Deal sells common stock to fund research, development, clinical trials
By Devika Patel
Knoxville, Tenn., July 8 - Cytokinetics, Inc. negotiated a $20 million at-the-money continuous public offering of stock on July 7, according to a prospectus supplement filed Thursday with the Securities and Exchange Commission. McNicoll, Lewis & Vlak LLC is the agent.
Proceeds will be used for research and development, including clinical trials for drug candidates, working capital and other general corporate purposes.
Cytokinetics is a biopharmaceutical company based in South San Francisco, Calif.
| Issuer: | Cytokinetics, Inc.
|
| Issue: | Common stock
|
| Amount: | $20 million
|
| Warrants: | No
|
| Agent: | McNicoll, Lewis & Vlak LLC
|
| Pricing date: | July 7
|
| Stock symbol: | Nasdaq: CYTK
|
| Stock price: | $1.21 at close July 7
|
| Market capitalization: | $88.83 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
